
Attilio Orazi, M.D., FRCPATH (ENGL)
Professor and Chair
Medical Director, University Medical Center of El Paso Laboratories
Anatomic Pathology and Hematopathology
-
Attilio Orazi M.D., FRCPath. (Engl.), received his M.D. from University of Milan, Italy, and trained in anatomic pathology, hematopathology and clinical hematology first in the United Kingdom and later at the Istituto Nazionale Tumori of Milan, Italy. He is board certified by the American Board of Pathology in anatomic pathology and hematopathology. In addition, he is board certified in clinical and laboratory hematology (EU/ Italy/). He is a fellow of the Royal College of Pathologists (England).
-
Medical licensed in Texas (full, active), New York (inactive), Indiana (inactive). Overseas license of the GMC, London, U.K.
-
He lists 360 published contributions which include 285 peer-reviewed medical journal articles and 76 book contributions primarily on hematopathology, including 14 chapters/sections of the 2008 WHO Classification of Tumors of Hematopoietic and Lymphoid tissue and 20 of the 2016 updated versions published in July 2017 by the IARC press.
-
He is the lead editor of Knowles’ Neoplastic Hematopathology 3rd edition (Lippincott Williams & Wilkins, 2014), co-editor of Diagnostic Bone Marrow Hematopathology (Cambridge Univ. Press, 2020) and of Hematopathology 3d edition (Elsevier in preparation, 2020-1). He is the lead author of Illustrated Pathology of the Bone Marrow (Cambridge Univ. Press, 2006). He is co-author of Benign and Reactive Conditions of Lymph Node and Spleen (American Registry of Pathology 2009) and of Disorders of the Spleen 2nd edition (Philadelphia: WB Saunders Co, 1999).
-
He served as a senior advisor for the 2016 update of the 4th edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues and as a CAC member for both 2008 and 2016 WHO editions.
-
Orazi has lectured extensively nationally (including at USCAP, ASH and ISLH) and internationally (25 countries). Lists many invited speaking engagements and key note lectures. He is a member of several editorial boards. His research interests include diagnostic integration and prognostic assessment in bone marrow neoplasms with a focus on chronic myeloid neoplasms and diagnostic challenges in spleen pathology.



















